- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.06. | P3 Health Partners Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.05. | P3 Health shares dip as TD Cowen cuts price target to $8 | 1 | Investing.com | ||
| 28.05. | P3 Health-Aktien fallen - TD Cowen Kursziel auf 8 US-Dollar senkt | 2 | Investing.com Deutsch | ||
| 16.05. | P3 Health Partners reaffirms $130M EBITDA improvement plan as operational initiatives accelerate in 2025 | 1 | Seeking Alpha | ||
| 15.05. | P3 Health Partners GAAP EPS of -$6.28 beats by $1.64, revenue of $373.2M beats by $11.13M | 1 | Seeking Alpha | ||
| 14.05. | What to Expect from P3 Health Partners' Earnings | 1 | Benzinga.com | ||
| 04.04. | P3 Health Partners Announces 1-for-50 Reverse Stock Split | - | Investing.com | ||
| P3 HEALTH PARTNERS Aktie jetzt für 0€ handeln | |||||
| 04.04. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| 01.04. | P3 Health Partners Inc. - S-8, Securities to be offered to employees in employee benefit plans | 2 | SEC Filings | ||
| 28.03. | P3 Health stock neutral rating reiterated after earnings miss | 2 | Investing.com | ||
| 28.03. | P3 Health Partners targets profitability in 2025 with adjusted EBITDA guidance of up to $5M | 1 | Seeking Alpha | ||
| 13.02. | P3 Health Partners strebt Profitabilität bis 2025 mit Umsatz von bis zu 1,5 Milliarden US-Dollar an | 11 | Investing.com Deutsch | ||
| 13.02. | P3 Health Partners Inc. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | P3 Health Partners Announces Third Quarter 2024 Results | 201 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen | |
| 07.08.24 | P3 Health Partners Announces Second Quarter 2024 Results | 151 | Business Wire | HENDERSON, Nev.--(BUSINESS WIRE)--P3 Health Partners Inc. ("P3" or the "Company") (NASDAQ: PIII), a patient-centered and physician-led population health management company, today announced its... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,109 | +3,81 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,745 | -2,49 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
| PING AN HEALTHCARE | 0,946 | +1,42 % | PA GOODDOCTOR (01833): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2025 | ||
| MOUNTAIN VALLEY MD | 0,014 | -5,41 % | Mountain Valley MD Holdings Inc: Mountain Valley hopes for continued growth in 2025 | ||
| CO-DIAGNOSTICS | 0,242 | +2,54 % | Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results | SALT LAKE CITY, March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the... ► Artikel lesen | |
| CYTOSORBENTS | 1,028 | -0,19 % | Cytosorbents Corp: CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb-ATR | PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive... ► Artikel lesen | |
| VERU | 0,565 | +9,51 % | Veru Inc.: Veru Reports Positive Results from Phase 2b QUALITY and Maintenance Extension Study Showing Enobosarm Significantly Reduced Body Weight Regain, Prevented Fat Regain, and Preserved Lean Mass After Semaglutide Discontinuation | --During the Maintenance Period of 12 weeks after discontinuing semaglutide (GLP-1 receptor agonist), placebo group regained 43% of body weight that was previously lost during Phase 2b QUALITY study... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Reports First Quarter 2025 Financial Results and Provides Business Update | Presented new amezalpat mechanism-of-action data reinforcing its potential as a novel cancer treatment at the 2025 AACR Annual MeetingGranted Orphan Drug designation by FDA for TPST-1495 for the treatment... ► Artikel lesen | |
| VOLITIONRX | 0,750 | -11,00 % | VolitionRx Limited Announces First Quarter 2025 Financial Results and Business Update | Conference call to discuss financial and operational results scheduled for Friday, May 16 at 8:30 a.m. U.S. Eastern Time
HENDERSON, Nev., May 15, 2025 /PRNewswire/... ► Artikel lesen | |
| EKSO BIONICS | 3,400 | -4,76 % | XFRA 23E0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILEKSO BIONICS. NEW... ► Artikel lesen | |
| IMUNON | 0,665 | +4,72 % | Imunon, Inc.: IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025 | ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism... ► Artikel lesen | |
| BEYOND AIR | 0,146 | +3,55 % | Beyond Air-Aktionäre genehmigen Reverse-Aktiensplit | ||
| AVINGER | 0,340 | -6,08 % | NSE - Avinger Inc - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| NOVACYT | 0,492 | -0,20 % | Novacyt S.A. - Result of AGM | ||
| AROVELLA THERAPEUTICS | 0,071 | +22,61 % | AROVELLA THERAPEUTICS LIMITED: Application for quotation of securities - ALA |
Das Unternehmen P3 HEALTH PARTNERS INC kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell +3,07 % bei einem Aktienkurs von 6,370 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu P3 HEALTH PARTNERS INC finden Sie auf Wallstreet Online.